Amgen (AMGN) Total Debt (2009 - 2026)
Amgen's quarterly Total Debt came in at $57.3 billion in Q1 2026, little changed year-on-year from $57.4 billion in Q1 2025, and up 4.98% quarter-over-quarter from $54.6 billion in Q4 2025.
Amgen has reported Total Debt for 18 years, with the latest figure at $57.3 billion in Q1 2026.
- For the quarter ending Q1 2026, Total Debt changed 0.1% year-over-year to $57.3 billion; the trailing twelve-month figure through Mar 2026 stood at $57.3 billion (changed 0.1% YoY), and the FY2025 full-year result was $54.6 billion, down 9.14% from the prior year.
- Total Debt for Q1 2026 stood at $57.3 billion, up from $54.6 billion in the prior quarter.
- The five-year high for Total Debt was $64.6 billion in Q4 2023, with the low at $36.5 billion in Q2 2022.
- Average Total Debt over 5 years is $54.5 billion, with a median of $57.4 billion recorded in 2025.
- Year-over-year, Total Debt surged 68.51% in 2023 and fell 10.37% in 2025.
- Tracing AMGN's Total Debt over 5 years: stood at $38.9 billion in 2022, then surged by 65.91% to $64.6 billion in 2023, then dropped by 6.99% to $60.1 billion in 2024, then declined by 9.14% to $54.6 billion in 2025, then advanced by 4.98% to $57.3 billion in 2026.
- The last three Total Debt figures came in at $57.3 billion (Q1 2026), $54.6 billion (Q4 2025), and $54.6 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 43.37 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 54.99 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 64.53 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 49.12 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 57.32 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 22.17 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 64.46 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 44.46 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 23.56 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 57.32 Bn |
| Dec 31, 2025 | 54.60 Bn |
| Sep 30, 2025 | 54.59 Bn |
| Jun 30, 2025 | 56.20 Bn |
| Mar 31, 2025 | 57.38 Bn |
| Dec 31, 2024 | 60.10 Bn |
| Sep 30, 2024 | 60.40 Bn |
| Jun 30, 2024 | 62.65 Bn |
| Mar 31, 2024 | 64.02 Bn |
| Dec 31, 2023 | 64.61 Bn |
| Sep 30, 2023 | 60.47 Bn |
| Jun 30, 2023 | 61.54 Bn |
| Mar 31, 2023 | 61.60 Bn |
| Dec 31, 2022 | 38.95 Bn |
| Sep 30, 2022 | 38.70 Bn |
| Jun 30, 2022 | 36.52 Bn |
| Mar 31, 2022 | 36.85 Bn |
| Dec 31, 2021 | 33.31 Bn |
| Sep 30, 2021 | 37.58 Bn |
| Jun 30, 2021 | 32.78 Bn |
| Mar 31, 2021 | 32.69 Bn |
| Dec 31, 2020 | 32.99 Bn |
| Sep 30, 2020 | 34.29 Bn |
| Jun 30, 2020 | 34.22 Bn |
| Mar 31, 2020 | 31.85 Bn |
| Dec 31, 2019 | 29.90 Bn |
| Sep 30, 2019 | 29.79 Bn |
| Jun 30, 2019 | 30.61 Bn |
| Mar 31, 2019 | 33.02 Bn |
| Dec 31, 2018 | 33.93 Bn |
| Sep 30, 2018 | 34.43 Bn |
| Jun 30, 2018 | 34.50 Bn |
| Mar 31, 2018 | 35.54 Bn |
| Dec 31, 2017 | 35.34 Bn |
| Sep 30, 2017 | 35.78 Bn |
| Jun 30, 2017 | 35.06 Bn |
| Mar 31, 2017 | 34.09 Bn |
| Dec 31, 2016 | 34.60 Bn |
| Sep 30, 2016 | 35.32 Bn |
| Jun 30, 2016 | 33.22 Bn |
| Mar 31, 2016 | 34.31 Bn |
| Dec 31, 2015 | 31.43 Bn |
| Sep 30, 2015 | 31.76 Bn |
| Jun 30, 2015 | 31.95 Bn |
| Mar 31, 2015 | 30.34 Bn |
| Dec 31, 2014 | 30.72 Bn |
| Sep 30, 2014 | 32.98 Bn |
| Jun 30, 2014 | 33.33 Bn |
| Mar 31, 2014 | 29.52 Bn |
| Dec 31, 2013 | 32.13 Bn |
| Sep 30, 2013 | 27.18 Bn |
| Jun 30, 2013 | 23.91 Bn |
| Mar 31, 2013 | 23.89 Bn |
| Dec 31, 2012 | 24.03 Bn |
| Sep 30, 2012 | 24.02 Bn |
| Dec 31, 2011 | 21.34 Bn |
| Mar 31, 2010 | 9.46 Bn |
| Dec 31, 2009 | 6.09 Bn |
| Sep 30, 2009 | 6.09 Bn |
| Jun 30, 2009 | 6.09 Bn |